|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
High-throughput DNA sequencing methods, such as next-generation sequencing using Illumina have yielded advancements in studies on MAPK signaling pathways and their association with AM; in particular, BRAF V600E is mediated by the activation of the Ras/Raf/MAPK pathway.
|
30489659 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Furthermore, our findings suggest that BRAF V600E mutations and epithelial-mesenchymal transition may act independently in the development of ameloblastoma.
|
30889301 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E expression in ameloblastomas-A 36-patient cohort from Helsinki University Hospital.
|
30811720 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The association between clinical-pathologic features and BRAF V600E mutation in ameloblastomas may provide directions for the treatment of this neoplasia.
|
29855709 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
<b>Conclusions:</b> The complete response observed here illustrate the role of molecular profiling in complicate clinical situation of rare head and neck cancer and the potential benefit of BRAF-targeted therapy in ameloblastoma carrying <i>BRAF</i> V600E mutation.
|
31781502 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF-V600E may contribute to metabolic alterations in ameloblastoma.
|
30739334 |
2019 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
The current research was launched to study the BRAF V600E mutation among a cohort of Iranian patients with ameloblastoma.
|
28650588 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation.
|
30208863 |
2018 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Although recent identification of BRAF V600E mutation and subsequent activation of mitogen-activated protein kinase (MAPK) pathway in ameloblastoma and odontogenic tumors provide additional options with targeted therapeutics, the molecular background of OKC is not well understood.
|
29103753 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Our findings suggest an association of BRAF-V600E with parameters of a more aggressive behaviour of ameloblastoma, supporting the future use of BRAF inhibitors for targeted therapy of this neoplasm.
|
27681305 |
2017 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
That this therapy was not effective in another primary cell culture led to the discovery of the oncogenic BRAF V600E mutation in a high proportion (63%) of ameloblastoma samples.
|
24749150 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
BRAF V600E was the most common mutation, found in 62% of ameloblastomas and in ameloblastic fibromas/fibrodentinomas but not in other odontogenic tumors.
|
24993163 |
2014 |
|
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
High frequency of BRAF V600E mutations in ameloblastoma.
|
24374844 |
2014 |